Back

The evolution of endothelial dysfunction according to the length of the implanted stent on the background of nebivolol therapy

1 September 2024 (13:00 - 13:30)
Organised by: Logo
Congress Presentation Part of: Coronary clot management: evolving strategies and techniques Adjunctive Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Lilia Simionov

Institute of Neurology and Neurosurgery of Moldova, Chisinau (Moldova (Republic of))

4 More presentations in this session

Presentation thumbnail
Clinical outcomes of immediate complete versus staged revascularization among STEMI patients and multivessel disease without cardiogenic shock: a meta-analysis.
Doctor J. Lim (Cebu City, PH)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of aspiration thrombectomy with intracoronary tirofiban VS aspiration thrombectomy alone in patients undergoing primary PCI: a systematic review and meta-analysis
Doctor G. Marcellana (Taguig, PH)
Abstract Slides Video
Presentation thumbnail
Short versus conventional DAPT in patients undergoing PCI with ultra-thin DES by renal function: an analysis from the HOST-IDEA trial
Professor J. Han (Seoul, KR)
Abstract Slides
Presentation thumbnail
Risk stratification using the academic research consortium high bleeding risk criteria in patients with atrial fibrillation undergoing percutaneous coronary intervention
Doctor Y. Tanabe (Chiba, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Coronary clot management: evolving strategies and techniques

The Event

Event poster

ESC Congress 2024

1 September 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease
thumbnail
Congress Presentation
The influence of endothelial dysfunction and the prognosis in patients with myocardial infarction with non-obstructive coronary arteries.
thumbnail
Congress Presentation
Empagliflozin significantly reduces circulating markers of endothelial dysfunction in Ischemia with Non-Obstructive Coronary Arteries (INOCA) and coronary microvascular dysfunction: a pilot trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources